Cell Cycle Markers in Focus: From Basic Research to Biomarker Discovery in Oncology

4. Emerging Tools and Technologies Used to Detect Cell Cycle Markers

5. Future Directions and Research Frontiers of Cell Cycle Markers

6. Cell Cycle Marker-associated Products

1. What Is the Cell Cycle?

The cell cycle is a meticulously ordered series of events leading to cell growth, DNA replication, and division into two daughter cells.

The eukaryotic cell cycle is usually divided into four primary stages:

G1 phase (Gap 1): The cell grows in size and synthesizes mRNA and proteins required for DNA replication.
S phase (DNA Synthesis): DNA is replicated, ensuring each daughter cell receives a full genetic complement.
G2 phase (Gap 2): The cell continues growth and prepares for mitosis, verifying DNA integrity.
M phase (Mitosis): The cell divides into two genetically identical cells.

A fifth state, G0, represents a quiescent or differentiated state outside the active cycle.

Progression through these phases is controlled by cyclin‑dependent kinases (CDKs), which are activated by cyclins and inhibited by CDK inhibitors (CKIs) such as p21 and p27. When this control system is intact, cells divide only when they should; when it is broken, uncontrolled proliferation and cancer can follow ^[1].

2. What Are Cell Cycle Markers?

Cell cycle markers are proteins whose expression levels or activity fluctuate in a periodic manner throughout the cell cycle. They serve as essential tools for identifying the current phase of a cell (G1, S, G2, or M), monitoring cell cycle progression, and understanding dysregulation of proliferation in diseases such as cancer ^[2]. These markers are crucial for both basic biological research and clinical applications, including cancer diagnosis, prognosis, and the development of targeted therapies ^[3].

Figure. Cell cycle markers at each phase of the cell cycle

Cell cycle markers can be categorized based on their functional roles and the specific phase of the cell cycle they indicate.

2.1 G1 Phase Markers

The G1 phase is a period of growth and preparation for DNA synthesis. Key regulators here determine whether a cell commits to division or exits to G0.

Cyclin D1 and CDK4/CDK6: The complex of cyclin D1 with CDK4/6 is a quintessential G1 regulator. It phosphorylates the retinoblastoma (Rb) protein, initiating the release of E2F transcription factors and progression towards the G1/S transition ^[4]. Its dysregulation is a common feature in many cancers.
p16(INK4a) and p15(INK4b): These are CKIs that specifically bind to and inhibit CDK4/6, thereby acting as negative regulators of the G1 phase. Deletions or loss of expression of p16 and p15 are frequent events in carcinogenesis, leading to unchecked G1 progression ^[5].
p21 and p27: These are broader CKIs that can inhibit various cyclin-CDK complexes. While they function in multiple phases, their role in arresting the cell cycle in G1 in response to DNA damage or differentiation signals is critical. The low expression of p21 and p27 is associated with poor prognosis in cancers like thymoma ^[6].

2.2 G1/S Transition and S Phase Markers

This checkpoint represents the irreversible commitment to DNA replication.

Cyclin E and CDK2: The cyclin E-CDK2 complex is activated late in G1 and is essential for the initiation of S phase. It further phosphorylates Rb and regulates pre-replication complex assembly. Its expression is tightly controlled, and aberrant expression can drive S-phase entry ^[7].
Cyclin A: While cyclin A expression begins in late G1, it peaks during S and G2 phases. It is associated with both CDK2 (in S phase) and CDK1 (in G2/M). Overexpression of cyclin A is a strong independent predictor of poor prognosis in cancers such as breast cancer, indicating highly proliferative tumors ^[8].
Cdc25 phosphatases: In higher-eukaryotic cells, Cdc25A mainly functions to regulate the G1/S transition. Cdc25B acts as a mitotic initiator, and Cdc25C assists in triggering cell entry into mitosis by dephosphorylating cyclin B/Cdk1.
E2F transcription factors: In mammalian cells, pocket proteins retinoblastoma protein, p107, and p130 bind to the E2F transcription factors, thus inhibiting transcription during the early G1 phase ^[33]. E2F1, E2F2, and E2F3 are found to be combined with RB during G1. E2F4 and E2F5 are found to be complexed with p130 in the quiescent (G0) phase and p107 and p130 in the G1 phase. The suppressive roles of E2F6, E2F7, and E2F8 are independent of pocket proteins. E2F6 accumulates when cells shift to the S phase and binds to target promoters to inhibit transcription.
Minichromosome maintenance (MCM) proteins: MCM proteins, specifically the MCM2-7 hexamer, are the essential replicative helicase in eukaryotic cells. They primarily ensure precise, once-per-cycle DNA replication. In the G1 phase, they license replication origins via pre-Replicative Complex (pre-RC) assembly to prevent aberrant re-replication. Activated at the G1/S transition, they form the Cdc45-MCM-GINS (CMG) helicase (with Cdc45 and GINS) to unwind DNA for S-phase genome duplication ^[34].

2.3 G2 Phase Markers

During G2, the cell prepares for mitosis, ensuring DNA replication is complete and undamaged.

Cyclin B1 and Cdc2 (CDK1): The cyclin B1-CDK1 complex (historically called MPF, Maturation Promoting Factor) is the master regulator of the G2/M transition. Its activity is kept in check by inhibitory phosphorylation on CDK1 by kinases like Wee1. The phosphatase CDC25C activates the complex by removing these phosphates, triggering entry into mitosis ^[9]. Altered expression of cdc2 is significantly higher in invasive cervical cancers compared to pre-invasive lesions and is strongly linked to infection with high-risk HPV types 16 and 18 ^[9].
ATM and Chk2: These are DNA damage checkpoint kinases that are crucial in G2. In response to DNA damage, they phosphorylate and inhibit CDC25C, preventing the activation of cyclin B1-CDK1 and arresting the cell in G2 to allow for repair ^[9].
CDCA2: It regulates the PP1γ-dependent DNA damage response during the cell cycle and helps maintain chromosome architecture for the interphase transition ^[14-16]. In hepatocellular carcinoma (HCC) cells, it promotes G1/S phase progression by upregulating cyclins and CDKs like CCND1/CDK4/6 and CCNE1/CDK2 ^[11].
CDCA3: A trigger for mitotic entry ^[17]. It acts as a component of the SCF (S phase kinase-associated protein 1/Cullin 1/F-box) E3 ubiquitin ligase complex, which mediates the destruction of the mitosis-inhibitory kinase Wee1 ^[18].

2.4 M Phase Markers

Mitosis involves chromosome segregation and cell division.

Cyclin B1-CDK1: As mentioned, this complex remains active throughout early mitosis, regulating nuclear envelope breakdown, spindle assembly, and chromosome condensation.
Histone H3 and Phospho-Histone H3 (Ser10): Phosphorylation of histone H3 at serine 10 is a specific epigenetic marker for chromatin condensation during mitosis and is widely used in immunohistochemistry to identify mitotic cells.
Structural Markers: Proteins involved in the mitotic spindle (e.g., tubulin) or the cytokinetic ring (e.g., Aurora kinases, Survivin) are also functional M-phase markers. Aurora A/B and PLK1 accumulate during the S phase and reach a peak in the G2/M phase, followed by a rapid degradation at the end of mitosis ^[35].
Cell division cycle-associated protein 1 (CDCA1/NUF2): It plays an important role in kinetochore functions and the spindle checkpoint by binding with KNTC2 ^[13].
CDCA4: It participates in spindle organization from prometaphase. Depletion of CDCA4 can cause accelerated cell proliferation ^[19].
CDCA5: It maintains the stable binding of sister chromatids during the S and G2/M phases of the cell cycle and the stability of DNA strands throughout the G2 phase ^[20,21].
CDCA6 (CBX2): It is an essential regulator of gene expression and developmental programs ^[22]. During cell division, CBX2 helps ensure the proper chromosomal segregation and prevents chromosomal abnormalities.
CDCA7: Defined as a c-Myc-responsive gene, CDCA7 plays a required role in both HELLS-dependent nucleosome remodeling and the maintenance of DNA methylation ^[23-25].
CDCA8: It is a crucial component of the chromosomal passenger complex (CPC), which regulates the dynamic localization of proteins during mitosis, ensuring proper chromosome segregation ^[12]. CDCA8 may be a potential biomarker for early HCC diagnosis and prognostic prediction ^[12].

2.5 Pan-Cell Cycle & Proliferation Markers

These markers are expressed in all active phases of the cycle (G1, S, G2, M) but not in G0, serving as general indicators of proliferative activity.

Ki-67: This is the most widely used proliferation marker. It is present in the nucleus of cells during G1, S, G2, and M phases but is absent in quiescent (G0) cells. A high Ki-67 index indicates a large growth fraction and is often associated with aggressive tumor behavior ^[8,10].
PCNA (Proliferating Cell Nuclear Antigen): Primarily involved in DNA replication (S phase), PCNA remains in the nucleus throughout the cell cycle and is also used as a proliferation marker.

3. Cell Cycle Markers in Oncology

In oncology, cell cycle markers also influence diagnosis, prognosis, and treatment choices.

3.1 Deregulation of cell cycle control in tumors

Cancer often involves sustained proliferative signaling and disrupted cell‑cycle checkpoints. Amplification or overexpression of cyclins, constitutive CDK activity, and loss of CKIs or p53‑pathway components are common events in many tumor types. These alterations not only drive growth but also change the landscape of cell‑cycle markers, typically increasing proliferation markers and shifting phase distributions ^[26].

Understanding these patterns can highlight vulnerabilities. Tumors with strong cyclin D–CDK4/6 dependency, for example, may respond to CDK4/6 inhibitors, and changes in proliferation markers during treatment can act as pharmacodynamic readouts ^[26].

3.2 Ki‑67 and proliferation indices in oncology

Ki‑67 has become a workhorse proliferation biomarker in cancer. In invasive breast cancer, the Ki‑67 labeling index is widely studied as a prognostic factor and is used in some guidelines to help stratify risk and support treatment decisions. High Ki‑67 often correlates with higher grade, increased metastatic potential, and poorer outcomes, although cutoffs and scoring methods vary between studies and centers [27-29].

Beyond breast cancer, Ki‑67 is used in grading neuroendocrine tumors and explored in many other malignancies. Reviews emphasize its clinical utility but also highlight pitfalls such as variability in antibodies, staining protocols, scoring, and intratumor heterogeneity, all of which need standardization for reliable use ^[27-29].

3.3 Cyclins, CDKs, and CKIs as biomarkers

Cyclin D1 overexpression, often due to gene amplification, is a classic example of a cell‑cycle regulator with biomarker potential, especially in certain lymphomas and breast cancers. CDKs themselves, particularly CDK4/6, are now therapeutic targets, and ongoing studies examine whether expression of these kinases or their downstream effects can predict response or resistance to inhibitors ^[26].

CKIs such as p16 are used diagnostically in some settings. For example, p16 immunostaining is a surrogate marker for oncogenic HPV in cervical and oropharyngeal lesions. Patterns of p21 and p27 expression have also been linked to prognosis in various cancers, reflecting their role as brakes on CDK activity ^[26,30].

4. Emerging Tools and Technologies Used to Detect Cell Cycle Markers

As research methods evolve, the study of cell cycle markers has expanded far beyond traditional microscopy. The new frontier focuses on real-time, high-dimensional insight into how cells behave and diversify.

4.1 Advances in Detection Techniques

Recent technologies are enabling the dynamic tracking to cell cycle markers within living systems.

Live-cell imaging now allows visualization of fluorescently tagged cyclins or reporters that signal transitions between phases.
High-throughput flow cytometry can analyze thousands of cells per second, capturing precise distributions of marker expression.
Single-cell sequencing adds another layer, linking transcriptomic states with cell cycle position in heterogeneous samples ^[31].

These methods are transforming the cell cycle from a static concept to a dynamic system observed in real time.

4.2 Omics and Systems Biology Approaches

Integrated "omics" approaches—combining proteomics, transcriptomics, and metabolomics—have deepened our understanding of cell cycle networks. Computational models now predict how signaling perturbations alter proliferation patterns.

Such strategies help researchers identify novel, context-specific markers, especially in cancer subtypes where regulatory circuits are rewired.

5. Future Directions and Research Frontiers of Cell Cycle Markers

Looking ahead, cell cycle research is converging with computational power and personalized medicine, promising even deeper insights into proliferation and control.

5.1 Integrating AI and Big Data

Artificial intelligence (AI) now plays a growing role in pattern recognition across imaging, genomic, and proteomic datasets. Algorithms can detect subtle variations in marker expression invisible to traditional analysis, accelerating biomarker validation pipelines ^[32].

5.2 Personalized Medicine and Predictive Markers

In precision oncology, the goal is to tailor therapies to each tumor’s proliferation signature. Cell cycle markers inform predictive models of drug response—helping clinicians distinguish patients who may benefit most from CDK inhibitors or DNA repair-targeting drugs.

This integration of molecular insight with clinical need marks the next evolution of translational cell biology.

6. Cell Cycle Marker-associated Products

Mounting studies have focused on cell cycle markers due to their important roles in assessing tumor progression and prognosis. Demand for products related to cell cycle markers has also increased. CUSABIO has been committed to providing high-quality scientific research products for the majority of scholars and scientific institutions. Here is a list of cell cycle marker-associated products.

Cell Cycle Markers	Cell Cycle Markers	Cell Cycle Markers	Cell Cycle Markers
E2F transcription factors	E2F1	p16(INK4a)	p16(INK4a)
	E2F2	p15(INK4b)	p15(INK4b)
	E2F3	p21	p21
	E2F4	p27	p27
	E2F5	ATM	ATM
	E2F6	Chk2	Chk2
	E2F7	Ki-67	Ki-67
	E2F8	MCM	MCM2
Cyclins	cyclin A1		MCM3
	cyclin A2		MCM4
	cyclin B1		MCM5
	cyclin B2		MCM6
	cyclin B3		MCM7
	cyclin D1		MCM10
	cyclin D2	Cdc25	Cdc25A
	cyclin D3		Cdc25B
	cyclin E1		Cdc25C
	cyclin E2	ORC	ORC1
	cyclin E		ORC2
Cdks	Cdk1		ORC3
	Cdk2		ORC4
	Cdk4		ORC5
	Cdk6		ORC6
PLK1	PLK1	Cdc6	Cdc6
CDCA	CDCA1/NUF1	Cdc45	Cdc45
	CDCA2	Cdt1	Cdt1
	CDCA3	Geminin	Geminin
	CDCA4	PCNA	PCNA
	CDCA5	Aurora A	Aurora A
	CDCA6	Aurora B	Aurora B
	CDCA7	H3S10PH	H3S10PH
	CDCA8	PLK1	PLK1

Conclusion

From foundational regulators like cyclins to clinical indicators such as Ki-67, cell cycle markers continue to bridge basic biology and medicine. They allow researchers to visualize growth, understand pathology, and forecast therapeutic outcomes.

As technology advances and interdisciplinary approaches expand, the study of cell cycle markers is poised to yield not only deeper biological understanding but also tangible clinical advances. The cell cycle, once viewed as a series of static steps, is now appreciated as a dynamic landscape that continues to generate critical insights into cancer and beyond.

References

[1] Pellarin, I., Favero, A., et al. (2025). Cyclin-dependent protein kinases and cell cycle regulation in biology and disease [J]. Signal Transduction and Targeted Therapy, 10, 11.

[2] ZHONG, J., LIU, J., et al. (2025). Cell cycle proteins: Linking the cell cycle to tumors [J]. Oncology Research, 33(6), 1335.

[3] Otto, T., & Sicinski, P. (2017). Cell cycle proteins as promising targets in cancer therapy [J]. Nature Reviews. Cancer, 17(2), 93.

[4] Michalides R. Prognosis for G1 cell-cycle regulators: useful for predicting course of disease and for assessment of therapy in cancer [J]. J Pathol. 1999 Aug;188(4):341-3.

[5] Swellam, M., El-Arab, L. R. E., & Adly, A. (2008). Prognostic value of cell-cycle regulators and cellular biomarkers in laryngeal squamous cell carcinoma [J]. Clinical Biochemistry, 41(13), 1059-1066.

[6] Mineo, T. C., Ambrogi, V., Mineo, D., & Baldi, A. (2005). Long-term disease-free survival of patients with radically resected thymomas [J]. Cancer, 104(10), 2063-2071.

[7] Bogdanovic Lj, Radojevic-Skodric S, et al. Immunohistochemical detection of cyclin E in transitional cell carcinoma [J]. J BUON. 2011 Oct-Dec;16(4):727-32.

[8] Michalides, R., Balkenende, A., et al. (2002). Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment [J]. British Journal of Cancer, 86(3), 402.

[9] Hashiguchi Y, Tsuda H, et al. Relationship between HPV typing and the status of G2 cell cycle regulators in cervical neoplasia [J]. Oncol Rep. 2004 Sep;12(3):587-91.

[10] Huang, J. X., Yan, W., Song, et al. (2005). Relationship between proliferative activity of cancer cells and clinicopathological factors in patients with esophageal squamous cell carcinoma [J]. World Journal of Gastroenterology: WJG, 11(19), 2956.

[11] Wang, J., Liu, X., Chu, H., & Chen, J. (2022). Cell division cycle associated 2 (CDCA2) upregulation promotes the progression of hepatocellular carcinoma in a p53-dependant manner [J]. PeerJ, 10, e13535.

[12] Cui, H., Peng, J., Li, Z., Lyu, J., Zhu, F., & Qin, H. (2021). Cell division cycle associated 8: A novel diagnostic and prognostic biomarker for hepatocellular carcinoma [J]. Journal of Cellular and Molecular Medicine, 25(24), 11097.

[13] DeLuca JG, Howell BJ, et al. Nuf2 and Hec1 Are Required for Retention of the Checkpoint Proteins Mad1 and Mad2 to Kinetochores [J]. Curr Biol (2003) 13(23):2103–9.

[14] Thadani R, Uhlmann F, Heeger S. Condensin, Chromatin Crossbarring and Chromosome Condensation [J]. Curr Biol (2012) 22(23): R1012–21.

[15] Peng A, Lewellyn AL, Schiemann WP, Maller JL. Repo-Man Controls a Protein Phosphatase 1-Dependent Threshold for DNA Damage Checkpoint Activation [J]. Curr Biol (2010) 20(5):387–96.

[16] Vagnarelli P. Repo-Man at the Intersection of Chromatin Remodelling, DNA Repair, Nuclear Envelope Organization, and Cancer Progression [J]. Adv Exp Med Biol (2014) 773:401–14.

[17] Ayad NG, Rankin S, et al. Tome-1, a Trigger of Mitotic Entry, Is Degraded During G1 via the APC [J]. Cell (2003) 113(1):101–13.

[18] Yoshida K. Cell-Cycle-Dependent Regulation of the Human and Mouse Tome-1 Promoters [J]. FEBS Lett (2005) 579(6):1488–92.

[19] Wang L, Zhu G, Yang D, Li Q, Li Y, Xu X, et al. The Spindle Function of CDCA4 [J]. Cell Motil Cytoskeleton (2008) 65(7):581–93.

[20] Ladurner R, Kreidl E, et al. Sororin Actively Maintains Sister Chromatid Cohesion [J]. EMBO J (2016) 35(6):635–53.

[21] Watrin E, Demidova M, Watrin T, Hu Z, Prigent C. Sororin Pre-mRNA Splicing Is Required for Proper Sister Chromatid Cohesion in Human Cells [J]. EMBO Rep (2014) 15(9):948–55.

[22] Vincenz C, Kerppola TK. Different Polycomb Group CBX Family Proteins Associate With Distinct Regions of Chromatin Using Nonhomologous Protein Sequences [J]. Proc Natl Acad Sci USA (2008) 105(43):16572–7.

[23] Prescott JE, Osthus RC, et al. A Novel C-Myc-Responsive Gene, JPO1, Participates in Neoplastic Transformation [J]. J Biol Chem (2001) 276(51):48276–84.

[24] Thijssen PE, Ito Y, Grillo G, et al. Mutations in CDCA7 and HELLS Cause Immunodeficiency-Centromeric Instability-Facial Anomalies Syndrome [J]. Nat Commun (2015) 6:7870.

[25] Jenness C, Giunta S, et al. HELLS and CDCA7 Comprise a Bipartite Nucleosome Remodeling Complex Defective in ICF Syndrome [J]. Proc Natl Acad Sci USA (2018) 115(5): E876–85.

[26] Pellarin, I., Favero, A., et al. (2025). Cyclin-dependent protein kinases and cell cycle regulation in biology and disease [J]. Signal Transduction and Targeted Therapy, 10, 11.

[27] Menon SS, Guruvayoorappan C, Sakthivel KM, Rasmi RR. Ki-67 protein as a tumour proliferation marker [J]. Clin Chim Acta. 2019 Apr;491:39-45.

[28] Davey MG, Hynes SO, Kerin MJ, Miller N, Lowery AJ. Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer [J]. Cancers (Basel). 2021 Sep 3;13(17):4455.

[29] Li LT, Jiang G, Chen Q, Zheng JN. Ki67 is a promising molecular target in the diagnosis of cancer (review) [J]. Mol Med Rep. 2015 Mar;11(3):1566-72.

[30] Sun, X., Bizhanova, A., et al. (2017). Ki-67 Contributes to Normal Cell Cycle Progression and Inactive X Heterochromatin in p21 Checkpoint-Proficient Human Cells [J]. Molecular and Cellular Biology, 37(17), e00569-16.

[31] Buettner F, Natarajan KN, et al. Computational analysis of cell-to-cell heterogeneity in single-cell RNA-sequencing data reveals hidden subpopulations of cells [J]. Nat Biotechnol. 2015 Feb;33(2):155-60.

[32] Esteva, A., Robicquet, A., Ramsundar, B. et al. A guide to deep learning in healthcare [J]. Nat Med 25, 24–29 (2019).

[33] Cosetta Bertoli, Jan M. Skotheim, et al. Control of cell cycle transcription during G1 and S phases [J]. Nat Rev Mol Cell Biol. 2013 Aug; 14(8): 518–528.

[34] Malysa, A., Zhang, X. M., & Bepler, G. (2024). Minichromosome Maintenance Proteins: From DNA Replication to the DNA Damage Response. Cells, 14(1), 12.

[35] Kulkarni AA, Loddo M, et al. DNA replication licensing factors and aurora kinases are linked to aneuploidy and clinical outcome in epithelial ovarian carcinoma [J]. Clin Cancer Res 2007, 13: 6153–6161.